Treatment with oral etoposide for childhood recurrent ependymomas

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 9, 2005, Pages 486-490

  Sandri, Alessandro ^a   Massimino, Maura ^b   Mastrodicasa, Luana ^a   Sardi, Nicola ^a   Bertin, Daniele ^a   Basso, Maria Eleonora ^a   Todisco, Liana ^a   Paglino, Alessandra ^c   Perilongo, Giorgio ^d   Genitori, Lorenzo ^e   Valentini, Laura ^f   Ricardi, Umberto ^a   Gandola, Lorenza ^b   Giangaspero, Felice ^g   Madon, Enrico ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f DEPARTMENT OF NEUROSURGERY   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Child; Ependymoma; Etoposide; Oral administration; Recurrence

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; METHOTREXATE; VINCRISTINE;

ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; EPENDYMOMA; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; EPENDYMOMA; ETOPOSIDE; FEMALE; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 25844463600     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000181430.71176.b7     Document Type: Article

References (34)

1. Teo C, Nakaji P, Symons P, et al. Ependymoma. Childs Nerv Syst. 2003; 19:270-285.
2. Jaing TH, Wang HS, Tsay PK, et al. Multivariate analysis of clinical prognostic factors in children with intracranial ependymomas. J Neurooncol. 2004;68:255-261.
3. Kalifa C, Valteau D, Pizer B, et al. High-dose chemotherapy in childhood brain tumours. Childs Nerv Syst. 1999;15:498-505.
4. Bouffet E, Perilongo G, Canete A, et al. Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol. 1998;30:319-331.
5. Ashley DM, Meier L, Kerby T, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol. 1996;14: 1922-1927.
6. Chamberlain MC, Kormanik PA. Chronic oral VP-16 for recurrent medulloblastoma. Pediatr Neurol. 1997;17:230-234.
7. Needle MN, Molloy PT, Geyer JR, et al. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol. 1997;29:28-32.
8. Chamberlain MC. Recurrent brainstem gliomas treated with oral VP-16. J Neurooncol. 1993;15:133-139.
9. Fulton D, Urtasun R, Forsyth P. Phase II of prolonged oral therapy with etoposide (VP 16) for patients with recurrent malignant glioma. J Neurooncol. 1996;27:149-155.
10. Chamberlain MC. Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. Arch Neurol. 1997;54: 554-558.
11. Davidson A, Cowing R, Lowis S, et al. Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG). Eur J Cancer. 1997;33: 1816-1822.
12. Chamberlain MC, Grafe MR. Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. J Clin Oncol. 1995;13:2072-2076.
13. Chamberlain MC. Recurrent cerebellar gliomas: salvage therapy with oral etoposide. J Child Neurol. 1997;12:200-204.
14. Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumors of the Central Nervous System, 2nd ed. Berlin: Springer, 1993.
15. Massimino M, Gandola L, Giangaspero F, et al. Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. Int J Radiat Oncol Biol Phys. 2004;58:1336-1345.
16. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Hainswhorth JD, Greco FA. Etoposide: twenty years later. Ann Oncol. 1995;6:325-341.
18. Poplin EA, Liu PY, Delmore JE, et al. Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a Southwest Oncology Group study. Gynecol Oncol. 1999;74:432-435.
19. Kasseyet S, Astoul P, Boutin C. Results of phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura. Cancer. 1999;85:1740-1749.
20. Helmbold P, Hegemann B, Holzhausen HJ, et al. Low-dose oral etoposide monotherapy in adult Langerhans cell histiocytosis. Arch Dermatol. 1998; 134:1275-1278.
21. Kakolyris S, Samonis G, Koukourakis M, et al. Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am J Clin Oncol. 1998;21: 505-508.
22. Pusztai L, Walters RS, Valero V, et al. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. Am J Clin Oncol. 1998;21: 442-446.
23. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16: 405-410.
24. Planting AS, van der Burg ME, Goey SH, et al. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma. Eur J Cancer. 1996;32A: 2026-2028.
25. Schwartsmann G, Sprinz E, Kromfield M, et al. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy. J Clin Oncol. 1997;15:2118-2124.
26. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 1998;34:1514-1521.
27. Hande KR. Etoposide pharmacology. Semin Oncol. 1992;19:3-9.
28. Cavalli F, Sonntag RW, Jungi F, et al. VP16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep. 1978;62:473-475.
29. Slevin ML, Clark PI, Osborne RJ, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol. 1990;7:1333-1340.
30. Hande KR, Krozely MG, Greco FA, et al. Bioavailability of low-dose oral etoposide. J Clin Oncol. 1993;11:374-377.
31. Chamberlain MC. Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide. Pediatr Neurol. 2001;24:117-121.
32. Hainsworth JD, Johnson DH, Frazier SR, et al. Chronic administration of oral etoposide: a phase I trial. J Clin Oncol. 1989;7:396-401.
33. Chamberlain MC. Salvage chemotherapy for recurrent spinal cord ependymoma. Cancer. 2002;95:997-1002.
34. Goldwein JW, Glauser TA, Packer RJ, et al. Recurrent intracranial ependymomas in children: survival, patterns of failure, and prognostic factors. Cancer. 1990;66:557-563.